ArticleInternational journal of nanomedicine2025
Sericin-Assisted Green Synthesis of Gold Nanoparticles as Broad-Spectrum Antimicrobial and Biofilm-Disrupting Agents for Therapy of Bacterial Infection.
Article in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Sericin-Incorporated Borophene Nanosheets: A Biocompatible Composite Material for Detection of Antibiotics.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Recent Advances in Gold Nanoparticles as Antimicrobial Agents Against Pathogenic Bacteria: A Review (2022-2026).Applied biochemistry and biotechnology · 2026Review
- Fluconazole-Decorated Gold Nanoparticles as a Novel Therapeutic Strategy Against Carbapenem-ResistantInfection and drug resistance · 2026Article
- Gold Nanoparticles for Wound Healing in Animal Models.Nanomaterials (Basel, Switzerland) · 2025Review
- Bioengineered nanoparticles for targeted topical delivery in wound healing: advances and future outlook.Nanomedicine (London, England) · 2025Review
- Daidzein-Decorated Gold Nanoparticles as a Novel Antimicrobial Strategy Against Carbapenem-Resistant Enterobacteriaceae.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tens of millions of people die from wound infections globally each year, and nearly 80% of tissue infections are associated with bacterial biofilms. However, overuse of antibiotics can lead to bacterial resistance. Therefore, it is critical to develop simple and effective strategies to kill bacteria and remove biofilms. Methods: The present study used sericin as a reducing and stabilizing agent to synthesize sericin-gold nanoparticles (Ser-Au NPs) and tested its colloidal stability under different pH and salt concentration conditions. Subsequently, functional gold nanocomposites (Ser-Au@MMI) were synthesized by combining Ser-Au NPs with 2-mercapto-1-methylimidazole (MMI). The antimicrobial effect of Ser-Au@MMI was checked by MIC, antimicrobial activity test, and in vitro cytotoxicity was assessed using CCK-8 assay. In vitro anti-biofilm effect was observed by fluorescence microscopy and SEM. Finally, the anti-infective therapeutic efficacy of Ser-Au@MMI was determined in an in vivo rat-infected wound model. Results: Sericin as a reducing and stabilizing agent to synthesize Ser-Au NPs exhibited excellent colloidal stability under different pH and salt concentration conditions. The TEM, EDS, and XPS analyses confirmed the successful synthesis of Ser-Au@MMI. It exhibited higher antibacterial activity due to the synergistic effect of MMI and AuNP, which can achieve a bactericidal effect by destroying the integrity of bacterial cell walls and structure. In addition, Ser-Au@MMI Conclusion: Ser-Au@MMI nanocomposites are prepared through a facile and environmentally friendly strategy and have the advantages of excellent bactericidal effect and low toxicity, which has the potential for application as a broad-spectrum antimicrobial agent and biofilm disrupting agent in healthcare.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.